top of page
E3353_06 [ALT4bxxx].png

Pioneers in

combining machine

and human intelligence

to deliver best-in-class immunotherapies

EtcemblyTCRs-circles_5a.png
Accelerate
the path
to clinic
EtcemblyTCRs-circles_5a.png
One of the
top 15 techbio
start-ups as mentioned
by Sifted
EtcemblyTCRs-circles_5a.png
Unlock new
targets from
the immune
repertoire

Etcembly’s vision is to be the leader in mapping human immune repertoires, empowering humanity to predict, prevent and conquer diseases with unprecedented precision.

DOTS-for-Website_960x1080_1.png

Harnessing the immunesystem for a cancer-free future

ADVANCING IMMUNOTHERAPY THROUGH 
DEEP REPERTOIRE SEQUENCING

We’re inviting people who are living with or have survived cancer as well as healthy volunteers to participate in a research study to help us develop new treatments that harness the power of a patient’s own immune system to fight the disease.

OUR CHALLENGE

 

We aim to explore the unique immune drivers that contribute to cancer survival. By analyzing the immune repertoires of long-term survivors, we can uncover critical insights that will pave the way for new therapeutic strategies. Our goal is to engineer T Cell Receptors (TCRs) and antibodies that target cancer more effectively, using our cutting-edge platform, EMLy.

More about EMLy
DOTS-for-Website_960x1080_3.png
DOTS-for-Website_960x1080_2.png
Etcembly_Dots-PAttern_1c.png
Etcembly_Dots-PAttern_1c.png
Etcembly_ICONS_Read Repertoires_2.png

What we do

DEEP REPERTOIRE SEQUENCING

We utilize sophisticated sequencing technologies to analyze the immune repertoires of long-term cancer survivors, capturing the complexity and diversity of their immune responses.

Etcembly_Dots-PAttern_1c.png
Etcembly_Dots-PAttern_1c.png
Etcembly_ICONS_LLM-Large Language Model.png

LARGE LANGUAGE MODELS

By applying our industry leading large language models, we interpret vast datasets to identify patterns and correlations within immune responses, enhancing our understanding of cancer immunology.

Etcembly_Dots-PAttern_1c.png
Etcembly_Dots-PAttern_1c.png
Etcembly_ICONS_TCR engineering_v1.png

ENGINEERING TCRS AND ANTIBODIES

Our platform, EMLy, enables us to design and optimize TCRs and antibodies that can be used in immunotherapy, offering new hope for cancer treatment.

More about EMLy
DOTS-for-Website_960x1080_3.png
DOTS-for-Website_960x1080_4.png

Why it matters

Cancer survivors possess unique immune profiles that can reveal invaluable information about effective immune responses. By focusing on these individuals, we aim to develop targeted therapies that not only enhance survival but also improve the quality of life for patients worldwide.

Etcembly_Dots-PAttern_1c.png
Etcembly_Dots-PAttern_1c.png
Etcembly_ICONS_Patient=Targets 2.png
Pipeline

Pipeline to success

ETCEMBLY T CELL ENGAGER RECEPTOR PROGRAM

E3353_06 [ALT5c].png

As featured in

and

Join us on our journey

We invite researchers, clinicians, and stakeholders in the field of oncology to collaborate with us.

Together, we can unlock the potential of immune repertoire analysis and make strides in the development of next-generation immunotherapies.

DOTS-for-Website_960x1080_1.png
Etcembly_Dots-PAttern_1d.png
bottom of page